FZD8 and teratocarcinoma: The biotherapy effect of the soluble Fzd receptors against tumors was first presented by DeAlmeida et al. who demonstrated that soluble Fzd8 CRD domain could serve as a potential anti-tumor agent in teratocarcinoma cells (24).